AGC to manufacture Takara Bio's COVID-19 vaccine

By The Science Advisory Board staff writers

May 21, 2020 -- In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid DNA intermediates for a DNA SARS-CoV-2 vaccine, according to the firms.

The vaccine will be developed based on Osaka University and AnGes plasmid DNA products. AGC will bring over 10 years of expertise in plasmid production to the project and will leverage its manufacturing facilities in Asia, Europe, and the U.S.

The companies did not release expected development timelines.

If you like this content, please share it with a colleague!

Related Reading

NIIMBL funds new biopharmaceutical manufacturing projects
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that it is funding 14 new projects in technology, workforce...

Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...

Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...

Codiak presents preclinical results for modular vaccine platform
Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting.